Cymabay Therapeutics Inc (CBAY)

Overview

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a focus on developing and providing innovative therapies aimed at the treatment of liver and other chronic diseases. The company's strategic approach to drug development primarily targets novel treatments that have the potential to significantly improve the quality of life for patients dealing with debilitating diseases. Originally established as Metabolex, Inc., the company underwent rebranding to better reflect its expanded focus beyond metabolic disorders. With its incorporation in 1988 and headquartered in Fremont, California, CymaBay Therapeutics has evolved into a notable entity within the biopharmaceutical sector. Noteworthy in its corporate journey is the transition to operating as a subsidiary of Gilead Sciences, Inc. as of March 22, 2024, marking a significant milestone in its journey towards advancing healthcare through innovative therapies.

Products and Services

• Seladelpar (MBX-8025)

A leading product candidate from CymaBay Therapeutics, Seladelpar, represents a groundbreaking advancement in the treatment of primary biliary cholangitis (PBC), a rare liver disease. By selectively agonizing the peroxisome proliferator activated receptor delta, Seladelpar has shown promise in clinical trials to offer a novel treatment pathway for patients suffering from PBC, who are in dire need of effective treatment options. The development and potential commercialization of Seladelpar have been supported through a licensing agreement with ABW Cyclops SPV LP, highlighting its significance in CymaBay's product portfolio.

• MBX-2982

Another critical component of CymaBay's product lineup is MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist currently being evaluated for potential benefits in subjects with type 1 diabetes. This investigational product represents the company's commitment to exploring and developing treatments that address a broad spectrum of chronic diseases, extending beyond liver diseases to include metabolic disorders such as diabetes.